RxDoctor Payments DataLook up a doctor →

Bassam Yaghmour, MD

Critical Care Medicine · Orange, CANPI 1710117288

Payments from drug & device makers

$4,406,459in general payments, 2019–2025

Across 497 payments — averaging $8866.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$3.6M
  • United Therapeutics Corporation$416K
  • Bayer$196K
  • Actelion Pharmaceuticals US, Inc.$174K
  • Pfizer$32K
  • Novartis$909
  • plus $498 from 7 others

What the payments were for

  • Consulting fees$46,47212%
  • Speaking & faculty fees$293,76878%
  • Travel & lodging$25,5137%
  • Food & beverage$10,5033%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,406,459 in reported general payments places this provider in the 95th percentile of 715 critical care medicine providers in California.

See all critical care medicine providers in California

Medicare billing

Part B allowed, 2024
$131,354
Medicare patients
264
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag39$841,745
OpsumitMacitentan70$833,120
WinrevairSotatercept-Csrk27$419,587
AdempasRiociguat17$263,261
OpsynviMacitentan/Tadalafil14$167,994
Ambrisentan39$155,100
AdcircaTadalafil15$63,247
Sildenafil Citrate67$28,479
Tadalafil36$23,346
EliquisApixaban14$12,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$10,238
Albuterol Sulfate HfaAlbuterol Sulfate49$2,315
Ventolin HfaAlbuterol Sulfate12$638
Furosemide31$182
Spironolactone28$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Opsynvi$173,642$1,842,859123 claims
MerckWinrevair$3,586,823$419,58727 claims
BayerAdempas$196,049$263,26117 claims
United Therapeutics CorporationAdcirca$416,230$63,24715 claims
PfizerEliquis$32,308$12,79214 claims
GSKTrelegy Ellipta$162$10,23819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 715 critical care medicine providers in California.

Other critical care medicine in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →